

A Study in Children and Adolescents on the Effectiveness of Takeda's Licensed Dengue Vaccine TDV Against Hospitalization Due to Dengue Disease

NCT06843226

Status	RECRUITING
Sponsor	Takeda
Enrollment	70,000 participants

Key Eligibility Criteria

Inclusion (16)

- Cohort:
- The participant is a child or adolescent eligible to be vaccinated with TDV as part of a vaccination program planned in the study area.
- The participant's family do not intend to migrate away from the cohort hospital catchment area within 3 years of his/her enrollment into the study cohort.
- The participant's parent or legally acceptable representative (LAR) signs and dates a written informed consent form (ICF), and any required privacy authorization where applicable, prior to the initiation of any study procedures, after the nature of the study has been explained according to local regulatory requirements.
- The participant signs and dates an age-appropriate assent form prior to the initiation of any study procedures, after the nature of the study has been explained according to local regulatory requirements.

... and 11 more (see full listing online)

Exclusion (9)

- Cases:
- To be eligible for inclusion as a case participants must not meet any of the following criteria:
- The participant has been vaccinated with TDV, a tetravalent, live attenuated, chimeric dengue vaccine in a yellow fever 17D backbone (CYD-TDV), or an investigational dengue vaccine prior to cohort enrollment.
- Contraindications as per the locally approved label/product information leaflet.
- Controls:

... and 4 more (see full listing online)

Locations (3 total)

Pattaya Patamakhun Hospital, Bang Lamung, Changwat Chon Buri, Thailand
Nakhon Phanom hospital, Nakhon Phanom, Changwat Nakhon Phanom, Thailand
Phra Nakhon Si Ayutthaya Hospital, Mueang Phra Nakhon Si Ayutthaya, Phra Nakhon Si Ayutthaya, Thailand